GlaxoSmithKline announces $139 million investment in Rockville

British drug giant GlaxoSmithKline PLC (NYSE: GSK) is investing $139 million to expand its Rockville manufacturing site, saying it needs extra capacity there to meet anticipated demand for its lupus drug. Already, the Rockville location manufactures a drug substance in bulk for Benlysta as an intravenous formulation. That substance is also used to make GSK's asthma drug Nucala and its drug for inhaled anthrax called raxibacumab. But now, GSK is hoping to boost that bulk production by about 50 perce nt. The…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news